世界の肺高血圧症市場は2022 年に 81 億 8,000 万ドルと評価され、2028年までに114億3,000万ドルに達する見込みです。肺動脈性肺高血圧症 (PAH) は、肺動脈としても知られる肺動脈における 25mmHg を超える血圧上昇を特徴とする、進行性の希少疾患です。PAH は男女を問わず罹患しますが、30 〜 60 歳の女性の間で多く見られます。残念ながら、PAH に対する既知の治療法はありませんが、症状を管理し、患者の生活の質を向上させるためにさまざまな治療選択肢があります。
PAHの有病率は長年にわたって増加しており、それが市場の成長に貢献しています。2022 年には米国で 37,000 人の患者が PAH を抱えており、米国外でも同様の患者がいると推定されています。女性の方がPAHを発症し易く、女性と男性の比率は3：1です。PAHの治療薬として承認されている薬剤は複数ありますが、いずれも患者の血行動態を改善することを重視しており、根本的な疾患を治療するものではありません。新薬候補は、疾患の原因に対処する新たな経路を標的としています。一方、肺動脈性肺高血圧症（PAH）の治療選択肢はここ数十年で増加しています。プロスタサイクリン、エンドセリン、NO 経路を標的とした薬物療法の出現によって、アウトカムは大幅に改善されました。PAH の新たに改良された治療法の開発によって、治療の選択肢が拡大し、患者管理が改善されました。また、PAH の根底にあるメカニズムの理解も進み、より良い症状制御と疾患管理を提供する標的療法の開発につながりました。2023 年から 2028 年までの予測期間中、市場は約6%の CAGR で成長すると予想されます。
目次
1. Executive Summary
2. Introduction
2.1 Pulmonary Arterial Hypertension: An Overview
2.1.1 Introduction to Pulmonary Arterial Hypertension
2.1.2 Symptoms of Pulmonary Arterial Hypertension
2.1.3 Pulmonary Arterial Hypertension Patient Subgroups
2.2 Pulmonary Arterial Hypertension Segmentation: An Overview
2.2.1 Pulmonary Arterial Hypertension Segmentation
3. Global Market Analysis
3.1 Global Pulmonary Arterial Hypertension Market: An Analysis
3.1.1 Global Pulmonary Arterial Hypertension Market: An Overview
3.1.2 Global Pulmonary Arterial Hypertension Market by Value
3.1.3 Global Pulmonary Arterial Hypertension Market by Drug Class (Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), sGC Stimulators, and pde-5 Inhibitors)
3.1.4 Global Pulmonary Arterial Hypertension Market by Type (Branded and Generic)
3.1.5 Global Pulmonary Arterial Hypertension Market by Route of Administration (Oral, Intravenous/ Subcutaneous, and Inhalation)
3.1.6 Global Pulmonary Arterial Hypertension Market by Distribution Channel (Hospital Pharmacies and Clinic, Retail Pharmacies, and Online Pharmacies)
3.1.7 Global Pulmonary Arterial Hypertension Market by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)
3.2 Global Pulmonary Arterial Hypertension Market: Drug Class Analysis
3.2.1 Global Pulmonary Arterial Hypertension Market by Drug Class: An Overview
3.2.2 Global Prostacyclin and Prostacyclin Analogs Pulmonary Arterial Hypertension Market by Value
3.2.3 Global Endothelin Receptor Antagonists Pulmonary Arterial Hypertension Market by Value
3.2.4 Global sGC Stimulators Pulmonary Arterial Hypertension Market by Value
3.2.5 Global pde-5 Inhibitors Pulmonary Arterial Hypertension Market by Value
3.3 Global Pulmonary Arterial Hypertension Market: Type Analysis
3.3.1 Global Pulmonary Arterial Hypertension Market by Type: An Overview
3.3.2 Global Branded Pulmonary Arterial Hypertension Market by Value
3.3.3 Global Generic Pulmonary Arterial Hypertension Market by Value
3.4 Global Pulmonary Arterial Hypertension Market: Route of Administration Analysis
3.4.1 Global Pulmonary Arterial Hypertension Market by Route of Administration: An Overview
3.4.2 Global Oral Pulmonary Arterial Hypertension Market by Value
3.4.3 Global Intravenous/ Subcutaneous Pulmonary Arterial Hypertension Market by Value
3.4.4 Global Inhalation Pulmonary Arterial Hypertension Market by Value
3.5 Global Pulmonary Arterial Hypertension Market: Distribution Channel Analysis
3.5.1 Global Pulmonary Arterial Hypertension Market by Distribution Channel: An Overview
3.5.2 Global Hospital Pharmacies & Clinics Pulmonary Arterial Hypertension Market by Value
3.5.3 Global Retail Pharmacies Pulmonary Arterial Hypertension Market by Value
3.5.4 Global Online Pharmacies Pulmonary Arterial Hypertension Market by Value
4. Regional Market Analysis
4.1 North America Pulmonary Arterial Hypertension Market: An Analysis
4.1.1 North America Pulmonary Arterial Hypertension Market: An Overview
4.1.2 North America Pulmonary Arterial Hypertension Market by Value
4.1.3 North America Pulmonary Arterial Hypertension Market by Region (The US, Canada, and Mexico)
4.1.4 The US Pulmonary Arterial Hypertension Market by Value
4.1.5 The US Pulmonary Arterial Hypertension Market by Drug Class (Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), sGC Stimulators, and pde-5 Inhibitors)
4.1.6 The US Prostacyclin and Prostacyclin Analogs Pulmonary Arterial Hypertension Market by Value
4.1.7 The US Endothelin Receptor Antagonists Pulmonary Arterial Hypertension Market by Value
4.1.8 The US sGC Stimulators Pulmonary Arterial Hypertension Market by Value
4.1.9 The US pde-5 Inhibitors Pulmonary Arterial Hypertension Market by Value
4.1.10 Canada Pulmonary Arterial Hypertension Market by Value
4.1.11 Mexico Pulmonary Arterial Hypertension Market by Value
4.2 Europe Pulmonary Arterial Hypertension Market: An Analysis
4.2.1 Europe Pulmonary Arterial Hypertension Market: An Overview
4.2.2 Europe Pulmonary Arterial Hypertension Market by Value
4.2.3 Europe Pulmonary Arterial Hypertension Market by Region (The UK, Germany, France, Italy, Spain, and Rest of Europe)
4.2.4 The UK Pulmonary Arterial Hypertension Market by Value
4.2.5 Germany Pulmonary Arterial Hypertension Market by Value
4.2.6 France Pulmonary Arterial Hypertension Market by Value
4.2.7 Italy Pulmonary Arterial Hypertension Market by Value
4.2.8 Spain Pulmonary Arterial Hypertension Market by Value
4.2.9 Rest of Europe Pulmonary Arterial Hypertension Market by Value
4.3 Asia Pacific Pulmonary Arterial Hypertension Market: An Analysis
4.3.1 Asia Pacific Pulmonary Arterial Hypertension Market: An Overview
4.3.2 Asia Pacific Pulmonary Arterial Hypertension Market by Value
4.3.3 Asia Pacific Pulmonary Arterial Hypertension Market by Region (China, Japan, India, Australia, South Korea, and Rest of the Asia Pacific)
4.1.4 China Pulmonary Arterial Hypertension Market by Value
4.1.5 Japan Pulmonary Arterial Hypertension Market by Value
4.1.6 India Pulmonary Arterial Hypertension Market by Value
4.1.7 Australia Pulmonary Arterial Hypertension Market by Value
4.1.8 South Korea Pulmonary Arterial Hypertension Market by Value
4.1.9 Rest of Asia Pacific Pulmonary Arterial Hypertension Market by Value
4.4 Latin America Pulmonary Arterial Hypertension Market: An Analysis
4.4.1 Latin America Pulmonary Arterial Hypertension Market: An Overview
4.4.2 Latin America Pulmonary Arterial Hypertension Market by Value
4.5 Middle East & Africa Pulmonary Arterial Hypertension Market: An Analysis
4.5.1 Middle East & Africa Pulmonary Arterial Hypertension Market: An Overview
4.5.2 Middle East & Africa Pulmonary Arterial Hypertension Market by Value
5. Impact of COVID-19
5.1 Impact of COVID-19 on Global Pulmonary Arterial Hypertension Market
5.2 Post COVID-19 Impact on Global Pulmonary Arterial Hypertension Market
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Rising Number of Female Population
6.1.2 Growing Prevalence of Lung Cancer and Other Lung Related Disorders
6.1.3 Increasing Healthcare Expenditure
6.1.4 Rising Pharmaceutical Research and Development Spending
6.1.5 Rising Prevalence of PAH
6.1.6 Availability of Reimbursement
6.2 Challenges
6.2.1 Strict Regulatory Standards
6.2.2 High Development Cost
6.2.3 Limited Treatment Options
6.3 Market Trends
6.3.1 New Potential Drugs Development
6.3.2 Recent Advancements in Treatment
6.3.3 Technological Advancements
6.3.4 Increasing Generic Drugs
6.3.5 Increasing Awareness and Diagnosis of PAH
6.3.6 Automated Fluid Handling Systems with Machine Learning
7. Competitive Landscape
7.1 Global and The US ERA Pulmonary Arterial Hypertension Market Players: Drug Comparison
7.2 Global and The US NO Pathway Pulmonary Arterial Hypertension Market Players: Drug Comparison
7.3 Global and The US Prostacyclin Pulmonary Arterial Hypertension Market Players: Drug Comparison
7.4 Global Pulmonary Arterial Hypertension Market Players by Emerging Therapeutics
7.5 Global Pulmonary Arterial Hypertension Market Players by Early Stage Clinical Programs
8. Company Profiles
8.1 Bayer AG
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategy
8.2 Pfizer Inc.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategy
8.3 Johnson & Johnson
8.3.1 Business Overview
8.3.2 Operating Segment
8.3.3 Business Strategy
8.4 Novartis AG
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategy
8.5 Gilead Sciences, Inc.
8.5.1 Business Overview
8.5.2 Sales by Product
8.5.3 Business Strategy
8.6 Merck & Co., Inc.
8.6.1 Business Overview
8.6.2 Operating Segments
8.6.3 Business Strategy
8.7 GlaxoSmithKline Plc.
8.7.1 Business Overview
8.7.2 Sales by Products
8.7.3 Business Strategy
8.8 TEVA Pharmaceutical Industries Limited
8.8.1 Business Overview
8.8.2 Operating Segments
8.8.3 Business Strategy
8.9 United Therapeutics Corporation
8.9.1 Business Overview
8.9.2 Revenues by Product
8.9.3 Business Strategy
8.10 Keros Therapeutics, Inc.
8.10.1 Business Overview
8.10.2 Business Strategy
8.11 Liquidia Corporation
8.11.1 Business Overview
8.11.2 Business Strategy
8.12 Reviva Pharmaceutical Holdings, Inc.
8.12.1 Business Overview
8.12.2 Business Strategy
8.13 Resverlogix Corp.
8.13.1 Business Overview
8.13.2 Business Strategy
8.14 Tenax Therapeutics
8.14.1 Business Overview
8.14.2 Business Strategy
8.15 Aerovate Therapeutics, Inc.
8.15.1 Business Overview
8.15.2 Business Strategy
List of Figures
Figure 1: Symptoms of Pulmonary Arterial Hypertension
Figure 2: Pulmonary Arterial Hypertension Patient Subgroups
Figure 3: Pulmonary Arterial Hypertension Segmentation
Figure 4: Global Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 5: Global Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 6: Global Pulmonary Arterial Hypertension Market by Drug Class; 2022 (Percentage, %)
Figure 7: Global Pulmonary Arterial Hypertension Market by Type; 2022 (Percentage, %)
Figure 8: Global Pulmonary Arterial Hypertension Market by Route of Administration; 2022 (Percentage, %)
Figure 9: Global Pulmonary Arterial Hypertension Market by Distribution Channel; 2022 (Percentage, %)
Figure 10: Global Pulmonary Arterial Hypertension Market by Region; 2022 (Percentage, %)
Figure 11: Global Prostacyclin and Prostacyclin Analogs Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 12: Global Prostacyclin and Prostacyclin Analogs Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 13: Global Endothelin Receptor Antagonists Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Endothelin Receptor Antagonists Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 15: Global sGC Stimulators Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 16: Global sGC Stimulators Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 17: Global pde-5 Inhibitors Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 18: Global pde-5 Inhibitors Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 19: Global Branded Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 20: Global Branded Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 21: Global Generic Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 22: Global Generic Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 23: Global Oral Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 24: Global Oral Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 25: Global Intravenous/ Subcutaneous Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 26: Global Intravenous/ Subcutaneous Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 27: Global Inhalation Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 28: Global Inhalation Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 29: Global Hospital Pharmacies & Clinics Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 30: Global Hospital Pharmacies & Clinics Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 31: Global Retail Pharmacies Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 32: Global Retail Pharmacies Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 33: Global Online Pharmacies Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 34: Global Online Pharmacies Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 35: North America Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 36: North America Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 37: North America Pulmonary Arterial Hypertension Market by Region; 2022 (Percentage, %)
Figure 38: The US Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 39: The US Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 40: The US Pulmonary Arterial Hypertension Market by Drug Class; 2022 (Percentage, %)
Figure 41: The US Prostacyclin and Prostacyclin Analogs Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 42: The US Prostacyclin and Prostacyclin Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 43: The US Endothelin Receptor Antagonists Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 44: The US Endothelin Receptor Antagonists Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 45: The US sGC Stimulators Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 46: The US sGC Stimulators Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 47: The US pde-5 Inhibitors Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 48: The US pde-5 Inhibitors Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 49: Canada Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 50: Canada Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 51: Mexico Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 52: Mexico Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 53: Europe Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 54: Europe Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 55: Europe Pulmonary Arterial Hypertension Market by Region; 2022 (Percentage, %)
Figure 56: The UK Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 57: The UK Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 58: Germany Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 59: Germany Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 60: France Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 61: France Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 62: Italy Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 63: Italy Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 64: Spain Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 65: Spain Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 66: Rest of Europe Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 67: Rest of Europe Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 68: Asia Pacific Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Billion)
Figure 69: Asia Pacific Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Billion)
Figure 70: Asia Pacific Pulmonary Arterial Hypertension Market by Region; 2022 (Percentage, %)
Figure 71: China Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 72: China Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 73: Japan Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 74: Japan Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 75: India Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 76: India Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 77: Australia Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 78: Australia Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 79: South Korea Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 80: South Korea Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 81: Rest of Asia Pacific Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 82: Rest of Asia Pacific Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 83: Latin America Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 84: Latin America Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 85: Middle East & Africa Pulmonary Arterial Hypertension Market by Value; 2018-2022 (US$ Million)
Figure 86: Middle East & Africa Pulmonary Arterial Hypertension Market by Value; 2023-2028 (US$ Million)
Figure 87: Global Female Population Between Age of 30 to 60; 2018-2022 (Billion)
Figure 88: The US Estimated Number of New Cancer Cases, by Gender; 2022 (Percentage, %)
Figure 89: The US National Health Expenditure; 2021-2030 (US$ Trillion)
Figure 90: Global Spending on Pharmaceutical Research And Development; 2019-2028 (US$ Billion)
Figure 91: Bayer AG Net Sales by Segment; 2022 (Percentage, %)
Figure 92: Pfizer Inc. Revenue by Segment; 2022 (Percentage, %)
Figure 93: Johnson & Johnson Sales by Business Segment; 2022 (Percentage,%)
Figure 94: Novartis AG Net Sales by Segments; 2022 (Percentage, %)
Figure 95: Gilead Sciences, Inc. Sales by Product; 2022 (Percentage, %)
Figure 96: Merck & Co., Inc. Sales by Segments; 2022 (Percentage, %)
Figure 97: GlaxoSmithKline Plc. Sales by Product; 2022 (Percentage, %)
Figure 98: TEVA Pharmaceutical Industries Ltd., Revenues by Segment; 2022 (Percentage, %)
Figure 99: United Therapeutics Corporation Revenues by Product; 2022 (Percentage, %)
Table 1: Summary of Selected New Potential Drugs in the Treatment of PAH
Table 2: Global and The US ERA Pulmonary Arterial Hypertension Market Players; Currently Approved Drug Comparison
Table 3: Global and The US NO Pathway Pulmonary Arterial Hypertension Market Players; Currently Approved Drug Comparison
Table 4: Global and The US Prostacyclin Pulmonary Arterial Hypertension Market Players; Currently Approved Drug Comparison
Table 5: Global Pulmonary Arterial Hypertension Market Players by Early Stage Clinical Programs
